Long-term results from the phase 2 OVARIO trial (NCT03326193) highlight the effectiveness of niraparib plus bevacizumab as maintenance therapy in patients with advanced ovarian cancer.

Navigating 2025 Drug Pricing Policies webinar, panelists discussed the Most Favored Nation executive order, bills aimed at ...

There are molecular testing gaps in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) treatment, highlighting ...

Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, ...

Air pollution exposure, both before and after birth, significantly escalates the risk of respiratory infections in children.

Long-term exposure to water contaminants, even below the regulatory limits, significantly increases the risk of chronic ...

New research reveals critical gaps in treatment for advanced non–small cell lung cancer (NSCLC), emphasizing the need for ...

During the “Tech Innovations in Community Oncology” meeting from Tennessee Oncology, oncologists explore artificial ...

Panelists highlight that despite established guidelines, delays and gaps in molecular profiling—especially for KMT2A rearrangements—persist due to report complexity, misinterpretation, and ...

Panelists discuss how data systems and registries should focus on improving care quality rather than just reimbursement, with patient empowerment strategies that encourage individuals to advocate for ...

Significant gaps in arthritis subtype awareness among US adults underscore the need for improved health literacy and more ...

Artificial intelligence (AI) transforms oncology by enhancing decision-making, improving patient care, and streamlining ...